clinical trial · NCT04625270
A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation
Low Grade Ovarian Serous AdenocarcinomaOvarian Canceravutometinib (VS-6766)avutometinib (VS-6766) and defactinib
brief summary
This study will assess the safety and efficacy of avutometinib (VS-6766) monotherapy and in combination with defactinib in subjects with recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
started
Dec 21, 2020
primary completion
Nov 15, 2024
completion
Dec 1, 2026
last updated
Jan 29, 2025
detailed description
This is a multicenter, randomized, open-label Phase 2 study designed to evaluate safety and tolerability and preliminary efficacy of avutometinib (VS-6766) versus avutometinib (VS-6766) in combination with defactinib in subjects with molecularly profiled recurrent LGSOC.
official title
A Phase 2 Study of Avutometinib (VS-6766) (Dual RAF/MEK Inhibitor) Alone and In Combination With Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol